IM Cannabis (IMCC) Capital Expenditures Growth (1y) (2021 - 2025)
IM Cannabis (IMCC) Capital Expenditures Growth (1y) (2021 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 8.33% |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | -19.86% |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | -1.95% |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 73.63% |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -0.19% |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | -37.60% |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | -42.11% |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | IM Cannabis | 554,496.00 | -614,474.17 | 1.09 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -92.54% |
| Sep 30, 2025 | 94.64% |
| Dec 31, 2024 | -75.76% |
| Jun 30, 2024 | 65.42% |
| Mar 31, 2024 | 99.51% |
| Dec 31, 2023 | 138.35% |
| Jun 30, 2023 | 65.79% |
| Mar 31, 2023 | 43.54% |
| Dec 31, 2022 | -296.80% |
| Sep 30, 2022 | -52.70% |
| Jun 30, 2022 | 58.76% |
| Mar 31, 2022 | 25.60% |
| Dec 31, 2021 | -67.28% |
| Sep 30, 2021 | 1,258.71% |
| Jun 30, 2021 | -121.04% |
| Mar 31, 2021 | -14.02% |